WRWeranja Ranasinghe

Weranja Ranasinghe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weranja Ranasinghe has a total of 211 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The addition of PSMA PET in selecting candidates for prostate cancer focal therapy

    by Kylie Yen‐Yi Lim, Mohammad Asghari‐Jafarabadi, Arveen A. Kalapara, Julian Smith, Mark Frydenberg, Weranja Ranasinghe

    Objectives: This study aims to evaluate whether prostate‐specific membrane antigen (PSMA) PET improves detection of index lesions and refines patient selection for focal therapy (FT) compared with standard diagnostic pathways. Patients and methods: We performed a retrospective review of men who underwent radical prostatectomy (RP) between 2015 and 2023. Pre‐operative assessment included multiparametric MRI, PSMA PET/CT and transperineal prostate biopsy. RP whole‐mount histopathology served as the reference standard. Focal therapy eligibility was assessed, and diagnostic performance compared between standard‐of‐care selection criteria and criteria incorporating PSMA PET. Results: Sixty patients (26%) met SOC criteria for FT. On final RP histopathology, only 20/60 (33.3%) were truly eligible, with discordance most commonly due to bilateral clinically significant prostate cancer (80%). Incorporation of PSMA PET into the selection model improved specificity for appropriate FT selection from 80.3% to 89.7% and positive predictive value from 33.3% to 46.2%. For detection of outfield disease, addition of PSMA PET increased sensitivity to 75.5% and negative predictive value to 53.5%. Higher SUVmax was significantly associated with FT ineligibility (AUC 0.67), with an optimal cut‐point of SUVmax > 4.78 predicting unsuitable candidates. Conclusion: Only a small proportion of men fulfil criteria for focal therapy, with a high risk of bilateral or contralateral disease using MRI and biopsy alone. PSMA PET improves diagnostic accuracy by identifying outfield lesions and reducing inappropriate FT selection. These findings support integration of PSMA PET to optimise patient selection, with further studies in prospective focal therapy cohorts required.


  • Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?

    by Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, Eldho Paul, Richard O'SUllivan, Zita E. Ballok, Andrew Ryan, Shakher Ramdave, Dinesh Sivaratnam, Patrick Bowden, et al.

    Objectives: To analyse the utility of adding multiparametric magnetic resonance imaging (mpMRI) with 68 Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in detection of local recurrence (LR) and distant recurrence (DR) in patients with biochemical recurrence (BCR), by describing detection rates over time since radical prostatectomy (RP), describing detection rates at differing prostate‐specific antigen (PSA) intervals, and identifying clinicopathological factors that predict detection of recurrence on imaging. Patients and Methods: Patients with BCR after RP were identified from 2016 to 2020. Kaplan–Meier analysis was performed for LR and DR on mpMRI, 68 Ga‐PSMA PET/CT, and paired/combined scans, and multivariate regression was performed identifying predictors of LR and DR. Results: A total of 117 patients underwent 150 sets of paired scans for BCR after RP, at PSA thresholds 0.2, 0.5, and 1.0 ng/mL. The 68 Ga‐PSMA PET/CT had higher detection rates of DR at PSA levels of 1.0 ng/mL vs mpMRI (6.1%, 10%, 25% and 36% vs 3%, 6.7%, 6.3%, and 24%, respectively). Meanwhile, mpMRI had higher detection rate of LR than 68 Ga‐PSMA PET/CT (30.3%, 33.3%, 40.6%, and 40% vs 0%, 13.3%, 18.8%, and 32%, respectively). The detection rate for LR was significantly higher on MRI compared to PSMA at PSA levels of P < 0.001 and P = 0.001, respectively). The detection rate for DR was significantly higher on PSMA than MRI at PSA levels of 0.5–1.0 ng/mL ( P = 0.039). On multivariate analysis, PSA velocity was a statistically significant predictor of both LR and DR on MRI alone, PSMA alone, and combined results of paired PSMA and MRI, and International Society of Urological Pathology grade was a statistically significant predictor of DR on MRI. Conclusion: The mpMRI had a higher detection rate for LR, while 68 Ga‐PSMA PET/CT had a higher detection rate for DR. PSA velocity was a significant predictor of both LR and DR on both imaging modalities. In BCR after RP, addition of mpMRI with 68 Ga‐PSMA PET/CT may improve diagnosis of recurrent lesions and patient selection for treatment.


  • Open Access

    18F-fluorodeoxyglucose positron emission tomography combined with computed tomography for bladder cancer staging: Diagnostic accuracy and prognostic implications

    by Tran Ngoc An Huynh, Xinyi Wei, Samiha Arulshankar, Darren Lam, Kylie Yen-Yi Lim, James Huang, Nieroshan Rajarubendra, Kevin Chu, Scott Donnellan, Weranja Ranasinghe

    Background: Muscle-invasive bladder cancer has a poor prognosis. Accurate lymph node (LN) staging is crucial, yet conventional imaging demonstrates limited sensitivity for detecting metastasis, necessitating improved pre-operative assessment. Objectives: To evaluate the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) compared to computed tomography (CT) for LN staging in patients with bladder cancer(BC) undergoing radical cystectomy (RC), and to assess the impact of imaging-determined nodal status on survival outcomes. Methods: This retrospective study analyzed 138 patients who underwent RC and pelvic LN dissection (PLND) at a multisite tertiary institution from 2008 to 2021. All patients received either pre-operative CT or FDG-PET/CT within 8 weeks before RC and PLND. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value for detecting LN metastasis (LNM) were calculated using pathological analysis as the reference standard. Kaplan–Meier survival analysis and Cox regression were employed to assess overall survival (OS). Results: FDG-PET/CT exhibited higher sensitivity (70% vs. 23.3%) and PPV (70% vs. 38.46%) compared to CT, but lower specificity (78.57% vs. 85.7%). Survival outcomes showed statistically significant differences in OS between node-positive and node-negative groups in the FDG-PET/CT cohort, but not in the CT cohort. Conclusion: FDG-PET/CT provides superior sensitivity and PPV compared to CT for LN staging in BC, facilitating more accurate pre-operative evaluation. The improved prognostic stratification associated with FDG-PET/CT may guide individualized treatment strategies.


  • Open Access

    Optimising prostate cancer pathways: Improving post‐biopsy waiting times in a tertiary centre

    by Shayan Soroush, Sean Lim, Prachi Beniwal, Gavin Wei, Ying Lu, Kylie Yen‐Yi Lim, Kirsten Holden, Matt Harper, Scott Donnellan, Weranja Ranasinghe

    Objectives: To evaluate the effectiveness of a streamlined Prostate Cancer Care Pathway (PCCP) in reducing post‐biopsy waiting times and improving patient satisfaction in a high‐volume tertiary centre.Patients and Methods: Patients undergoing prostate biopsies were prospectively followed through PCCP for one year and were retrospectively compared to 150 patients who were treated at our centre either immediately prior to PCCP implementation (2022) or during Covid‐19 lockdowns (2020). Waiting times were compared using the Kruskal‐Wallis H‐test. Patient satisfaction was assessed using the modified PCa Questionnaire for Patients (PCQ‐P).Results: A total of 398 patients were included. 248 patients went through PCCP, compared with 75 patients pre‐PCCP implementation (2022) and 75 patients during the 2020 pandemic. The median time from biopsy to results post‐PCCP was 15.0 days (IQR 13.0–19.0). This was significantly shorter than pre‐PCCP introduction of 21.0 days (17.0–28.0) and during 2020 lockdowns, 18.0 days (14.0–21.0, p < 0.001). A total of 131 patients (52.8%) requiring treatment under PCCP were streamlined for multidisciplinary discussion following imaging at a median time of 38.0 (29.8–42.0) days and seen at Urology or Radiation Oncology Consultant clinic for treatment discussion at a median of 38.0 days (31.0–49.0), compared to 63.0 days (45.0–84.0) pre‐PCCP (2022) and 52.0 days in 2020 (38.0–75.0, p < 0.001). A total of 176 PCCP patients (70.1%) participated in PCQ‐P with 93.2% of participants reporting satisfaction with waiting time durations (n = 176).Conclusion: PCCP implementation reduced waiting times in all post‐biopsy care measures following significant Covid‐19 delays in PCa care delivery. Streamlining resources using similar pathways can reduce waiting times in cancer care and other conditions to alleviate anxiety during healthcare system strain.


  • Open Access

    Accuracy and limitations of ureteroscopic biopsy in the staging and grading of upper tract urothelial carcinoma: A retrospective analysis at a large tertiary center

    by Tran Ngoc An Huynh, Xinyi Wei, Samiha Arulshankar, James Huang, Nieroshan Rajarubendra, Kevin Chu, Matthew Harper, Scott Donnellan, Weranja Ranasinghe

    Background: Upper tract urothelial carcinoma (UTUC) poses significant diagnostic challenges due to the limitations of current staging and grading techniques. Ureteroscopic (URS) biopsy is widely used preoperatively, but its accuracy, compared to final pathology, remains variable. Objectives: To evaluate the accuracy and limitations of URS biopsy in the staging and grading of UTUC, using final pathological results from radical nephroureterectomy (RNU) as the reference standard. Methods: This retrospective study included 86 patients who underwent URS biopsy followed by RNU for UTUC at a tertiary institution between 2011 and 2023. Data were collected on patient demographics, tumor characteristics, imaging, and pathology results. The accuracy of URS biopsy in staging and grading was assessed, and its associations with pathological upstaging and non-diagnostic biopsies were statistically analyzed. Results: URS biopsy correctly staged 54.69% of tumors (κ = 0.311 [0.183 – 0.439], p<0.001) and correctly graded 70.93%. (κ = 0.447 [0.303 – 0.592], p<0.001). Pathological upstaging and upgrading occurred in 39.06% and 25.58% of cases, respectively. Non-diagnostic biopsies for both stage and grade were observed in 5.81% of cases, particularly in tumors located in the renal pelvis (p=0.0064). Complementary diagnostic tools, such as computed tomography urography (CTU) and urine cytology, showed limitations, with CTU detecting invasive disease in only 14.29% of cases and urine cytology identifying high-grade tumors in 11.11%. Conclusion: URS biopsy demonstrates limitations in accurately staging and grading UTUC, resulting in a risk of both undertreatment and overtreatment. A multimodal diagnostic approach incorporating imaging, cytology, and clinical judgment is essential to optimizing management decisions and improving oncological outcomes.


  • Open Access

    SIU-ICUD: Screening and Early Detection of Prostate Cancer

    by Ola Bratt, Mohamed Jalloh, Anwar R. Padhani, Paul F. Pinsky, Hein Van Poppel, Weranja Ranasinghe, Kamran Zargar-Shoshtari, Kai Zhang, Anssi Auvinen

    Background/Objectives: Randomised trials show that screening with prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to high rates of overdiagnosis. Today, improved diagnostic methods more selectively detect potentially lethal, high-grade prostate cancer. Methods: This is a narrative review of modern diagnostic methods, ongoing trials, national policies and knowledge gaps related to screening and early detection of prostate cancer. Results: Screening intervals can be prolonged in men with PSA values below around 1 ng/mL as these men are at very low long-term risk of prostate cancer death. Overdiagnosis can be reduced by magnetic resonance imaging (MRI) and lesion-targeted prostate biopsies. Risk calculators and ancillary biomarkers can select men for further investigation and thereby reduce resource needs. These new methods are evaluated in large, randomised screening trials. The remaining knowledge gaps include optimal PSA cut-offs, screening intervals, start and stop ages, and the long-term balance between benefits and harm. Until recently, almost no national healthcare authority recommended population-based screening for prostate cancer. Now, the European Union Council recommends an evaluation of the feasibility of organised, risk-stratified screening. This has led to several pilot projects. In some other parts of the world, such as sub-Saharan Africa and the Caribbean, such initiatives are lacking despite high prostate cancer mortality rates. Conclusions: Risk-stratified prostate cancer screening including MRI and targeted biopsy reduces overdiagnosis. Results from ongoing research are needed to optimise screening protocols and to define long-term benefits and harms. Initiatives for early detection and screening are emerging across the world but are still lacking in many countries with high prostate cancer mortality.


  • Utility of PSA free‐to‐total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL

    by Samuel Sii, Nathan Papa, Ting Wai Yiu, Jake Tempo, Liang Qu, Marlon Perera, Ian Thompson, Joseph Ischia, Neil Fleshner, Elliot Smith, et al.

    Objective: To investigate the relationship between the prostate‐specific antigen (PSA) free‐to‐total ratio (FTR) and International Society of Urological Pathology Grade Group ≥2, clinically significant prostate cancer (csPCa) in men with a low PSA level (≤4 ng/mL). Patients and Methods Data were obtained from the Prostate Cancer Prevention Trial. Patients with a PSA level of ≤4 ng/mL and who received a biopsy within a year of this PSA measurement were included. Associations between FTR and csPCa were investigated with logistic regression, adjusting for age and PSA, a re‐scaled Brier score (index of predictive accuracy), and decision curve analysis. Results: A total of 406 patients were analysed with 139 (34%) having csPCa and 204 (50%) having any grade PCa. For those with an FTR ≤0.15, 46% had csPCa, vs 22% for those with a ratio ≥0.20. In a regression model, the predicted probability of csPCa for a 60‐year‐old with a PSA of 3 ng/mL was 61% if the FTR was 0.05, falling to 18% if the FTR was 0.30. A clear negative relationship between increasing FTR and probability of csPCa was observed. A model containing FTR additional to PSA and age provides greater net benefit as per decision curve analysis and likely superior discrimination and calibration measured by a higher index of predictive accuracy. Conclusions: In middle‐aged men with a PSA level between 1.5 and 4 ng/mL but otherwise indicated for biopsy, a low FTR is associated with higher rates of csPCa. It should be utilised as an additional, readily available and inexpensive test to improve prediction of csPCa and aid in patient counselling.